JP2022524391A5 - - Google Patents
Info
- Publication number
- JP2022524391A5 JP2022524391A5 JP2021553767A JP2021553767A JP2022524391A5 JP 2022524391 A5 JP2022524391 A5 JP 2022524391A5 JP 2021553767 A JP2021553767 A JP 2021553767A JP 2021553767 A JP2021553767 A JP 2021553767A JP 2022524391 A5 JP2022524391 A5 JP 2022524391A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- oncolytic virus
- synthetic oncolytic
- synthetic
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024163492A JP2025011109A (ja) | 2019-03-08 | 2024-09-20 | 合成腫瘍溶解性ｌｎｐレプリコンｒｎａおよびがん免疫治療のための使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962815611P | 2019-03-08 | 2019-03-08 | |
| US62/815,611 | 2019-03-08 | ||
| PCT/US2020/013069 WO2020185293A1 (en) | 2019-03-08 | 2020-01-10 | Synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024163492A Division JP2025011109A (ja) | 2019-03-08 | 2024-09-20 | 合成腫瘍溶解性ｌｎｐレプリコンｒｎａおよびがん免疫治療のための使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022524391A JP2022524391A (ja) | 2022-05-02 |
| JP2022524391A5 true JP2022524391A5 (enExample) | 2023-01-23 |
| JP7561134B2 JP7561134B2 (ja) | 2024-10-03 |
Family
ID=69526302
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021553767A Active JP7561134B2 (ja) | 2019-03-08 | 2020-01-10 | 合成腫瘍溶解性ｌｎｐレプリコンｒｎａおよびがん免疫治療のための使用 |
| JP2024163492A Pending JP2025011109A (ja) | 2019-03-08 | 2024-09-20 | 合成腫瘍溶解性ｌｎｐレプリコンｒｎａおよびがん免疫治療のための使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024163492A Pending JP2025011109A (ja) | 2019-03-08 | 2024-09-20 | 合成腫瘍溶解性ｌｎｐレプリコンｒｎａおよびがん免疫治療のための使用 |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US11717548B2 (enExample) |
| EP (2) | EP3934673B1 (enExample) |
| JP (2) | JP7561134B2 (enExample) |
| KR (2) | KR20250171410A (enExample) |
| CN (1) | CN113966221B (enExample) |
| AU (1) | AU2020233788A1 (enExample) |
| BR (1) | BR112021017637A8 (enExample) |
| CA (1) | CA3132714A1 (enExample) |
| CO (1) | CO2021013417A2 (enExample) |
| DK (1) | DK3934673T3 (enExample) |
| ES (1) | ES3066636T3 (enExample) |
| FI (1) | FI3934673T3 (enExample) |
| IL (1) | IL285963A (enExample) |
| MX (1) | MX2021010808A (enExample) |
| MY (1) | MY207334A (enExample) |
| PH (1) | PH12021552145A1 (enExample) |
| PT (1) | PT3934673T (enExample) |
| SG (1) | SG11202109514VA (enExample) |
| WO (1) | WO2020185293A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN121971599A (zh) | 2019-02-25 | 2026-05-05 | 芝加哥大学 | 用与抗炎剂连接的ecm亲和肽治疗炎症性和自身免疫性病症的方法和组合物 |
| KR20250171410A (ko) * | 2019-03-08 | 2025-12-08 | 메사추세츠 인스티튜트 오브 테크놀로지 | 합성 종양용해성 lnp-레플리콘 rna 및 암 면역요법을 위한 용도 |
| CZ310613B6 (cs) | 2020-09-23 | 2026-01-28 | Ústav organické chemie a biochemie AV ČR, v. v. i. | Lipidoidy pro transfekci nukleových kyselin a jejich použití |
| CN113509542A (zh) * | 2021-04-20 | 2021-10-19 | 嘉晨西海(杭州)生物技术有限公司 | 一种基于mRNA的表达白介素12针对肿瘤的药物及其制备方法 |
| CZ310443B6 (cs) | 2021-07-19 | 2025-06-25 | Ústav organické chemie a biochemie AV ČR, v. v. i. | Cyklohexanové lipidoidy pro transfekci nukleových kyselin a jejich použití |
| IL316186A (en) | 2022-04-26 | 2024-12-01 | Strand Therapeutics Inc | Lipid nanoparticles containing Venezuelan equine encephalitis (VEE) replicon and uses thereof |
| CN115227674B (zh) * | 2022-08-05 | 2023-07-04 | 武汉滨会生物科技股份有限公司 | 包封的溶瘤病毒遗传物质及其应用 |
| JP2026502453A (ja) * | 2023-01-12 | 2026-01-23 | バヴァリアン・ノルディック・アクティーゼルスカブ | がんワクチンのための組み換え改変ｓａＲＮＡ（ＶＲＰ） |
| WO2024211865A2 (en) * | 2023-04-07 | 2024-10-10 | Omega Therapeutics, Inc. | Lipids and lipid-like compounds for therapeutic lipid nanoparticle (lnp) delivery |
| CN118147171B (zh) * | 2024-03-08 | 2024-12-06 | 上海复诺健生物科技有限公司 | 具有增强的外源基因表达水平的自扩增mRNA核酸序列 |
| KR20260046366A (ko) | 2023-07-25 | 2026-04-07 | 스트랜드 세러퓨틱스 인코포레이티드 | 마이크로 rna 비표적화 센서를 포함하는 폴리뉴클레오타이드 및 이의 용도 |
| WO2025087372A1 (zh) * | 2023-10-27 | 2025-05-01 | 上海元宋生物技术有限公司 | 溶瘤病毒及其用途 |
| CN119479778B (zh) * | 2024-10-16 | 2025-04-25 | 北京悦康科创医药科技股份有限公司 | 一种lnp转染效率预测模型构建方法及装置 |
| CN121081290B (zh) * | 2025-11-12 | 2026-03-10 | 佑嘉(杭州)生物医药科技有限公司 | 一种毛囊靶向递送系统及生发防脱化妆品 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| EP2451475A2 (en) * | 2009-07-06 | 2012-05-16 | Novartis AG | Self replicating rna molecules and uses thereof |
| US11291635B2 (en) * | 2010-07-06 | 2022-04-05 | Glaxosmithkline Biological Sa | Virion-like delivery particles for self-replicating RNA molecules |
| CA2841047A1 (en) * | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic compositions and uses thereof |
| WO2014089061A1 (en) * | 2012-12-03 | 2014-06-12 | Yasuko Rikihisa | Ehrlichial invasin for immunization, diagnosis, and cell delivery |
| CN107072946B (zh) * | 2014-09-05 | 2022-01-11 | 诺华股份有限公司 | 用于递送活性剂的脂质和脂质组合物 |
| RU2739794C2 (ru) * | 2014-10-31 | 2020-12-28 | Массачусетс Инститьют Оф Текнолоджи | Доставка биомолекул в клетки иммунной системы |
| WO2016187531A1 (en) * | 2015-05-21 | 2016-11-24 | Ohio State Innovation Foundation | Benzene-1,3,5-tricarboxamide derivatives and uses thereof |
| KR20250171410A (ko) * | 2019-03-08 | 2025-12-08 | 메사추세츠 인스티튜트 오브 테크놀로지 | 합성 종양용해성 lnp-레플리콘 rna 및 암 면역요법을 위한 용도 |
| CN116710079A (zh) * | 2020-07-24 | 2023-09-05 | 斯特兰德生物科技公司 | 包含经修饰的核苷酸的脂质纳米颗粒 |
| US20240140960A1 (en) * | 2021-02-12 | 2024-05-02 | Ohio State Innovation Foundation | Sugar derived lipid nanomaterials and uses thereof |
| CN117897494A (zh) * | 2021-07-09 | 2024-04-16 | 瑞普利科特生物科学公司 | 经修饰的东方马脑炎病毒、自复制rna构建体及其用途 |
| CN117180454A (zh) * | 2022-05-16 | 2023-12-08 | 上海行深生物科技有限公司 | 含有自复制rna分子和脂质纳米颗粒递送载体的组合物及其制备方法 |
-
2020
- 2020-01-10 KR KR1020257038746A patent/KR20250171410A/ko active Pending
- 2020-01-10 US US16/739,407 patent/US11717548B2/en active Active
- 2020-01-10 MY MYPI2021005045A patent/MY207334A/en unknown
- 2020-01-10 SG SG11202109514VA patent/SG11202109514VA/en unknown
- 2020-01-10 JP JP2021553767A patent/JP7561134B2/ja active Active
- 2020-01-10 MX MX2021010808A patent/MX2021010808A/es unknown
- 2020-01-10 PH PH1/2021/552145A patent/PH12021552145A1/en unknown
- 2020-01-10 EP EP20704372.0A patent/EP3934673B1/en active Active
- 2020-01-10 BR BR112021017637A patent/BR112021017637A8/pt unknown
- 2020-01-10 FI FIEP20704372.0T patent/FI3934673T3/fi active
- 2020-01-10 ES ES20704372T patent/ES3066636T3/es active Active
- 2020-01-10 DK DK20704372.0T patent/DK3934673T3/da active
- 2020-01-10 WO PCT/US2020/013069 patent/WO2020185293A1/en not_active Ceased
- 2020-01-10 EP EP25227099.6A patent/EP4729621A2/en active Pending
- 2020-01-10 CA CA3132714A patent/CA3132714A1/en active Pending
- 2020-01-10 PT PT207043720T patent/PT3934673T/pt unknown
- 2020-01-10 AU AU2020233788A patent/AU2020233788A1/en active Pending
- 2020-01-10 CN CN202080034343.3A patent/CN113966221B/zh active Active
- 2020-01-10 KR KR1020217032460A patent/KR102889984B1/ko active Active
-
2021
- 2021-08-30 IL IL285963A patent/IL285963A/en unknown
- 2021-10-07 CO CONC2021/0013417A patent/CO2021013417A2/es unknown
-
2023
- 2023-06-14 US US18/334,449 patent/US12383589B2/en active Active
-
2024
- 2024-09-20 JP JP2024163492A patent/JP2025011109A/ja active Pending
-
2025
- 2025-07-09 US US19/264,067 patent/US20260061013A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3934673T3 (fi) | Synteettinen onkolyyttinen lnp-replikoni-rna ja sen käyttöjä syövän immunoterapiaan | |
| Huang et al. | A bimetallic nanoplatform for STING activation and CRISPR/Cas mediated depletion of the methionine transporter in cancer cells restores anti-tumor immune responses | |
| Yaremenko et al. | Clinical advances of mRNA vaccines for cancer immunotherapy | |
| Li et al. | mRNA vaccine in cancer therapy: Current advance and future outlook | |
| Parato et al. | Recent progress in the battle between oncolytic viruses and tumours | |
| Nadeem et al. | A Virus‐Spike Tumor‐Activatable Pyroptotic Agent | |
| Liong et al. | Multifunctional inorganic nanoparticles for imaging, targeting, and drug delivery | |
| Ladak et al. | The current Landscape of mRNA vaccines against viruses and cancer–a mini review | |
| Strods et al. | Preparation by alkaline treatment and detailed characterisation of empty hepatitis B virus core particles for vaccine and gene therapy applications | |
| JP2023535225A5 (enExample) | ||
| Bahreyni et al. | A combination of genetically engineered oncolytic virus and melittin-CpG for cancer viro-chemo-immunotherapy | |
| Hromic-Jahjefendic et al. | Viral vector-based melanoma gene therapy | |
| Zhang et al. | Self‐Oxygenated biomimetic nanozyme for tumor catalytic immunotherapy | |
| Vasilevska et al. | Semliki Forest virus biodistribution in tumor-free and 4T1 mammary tumor-bearing mice: a comparison of transgene delivery by recombinant virus particles and naked RNA replicon | |
| Newman et al. | Infection: a cause of and cure for cancer | |
| Rachamala | Translational Advances in Lipid Nanoparticle Drug Delivery Systems for Cancer Therapy: Current Status and Future Horizons | |
| Ghazizadeh et al. | Advances in cancer nanovaccines: a focus on colorectal cancer | |
| Anjum et al. | Co‐delivery of oncolytic virus and chemotherapeutic modality: Vincristine against prostate cancer treatment: A potent viro‐chemotherapeutic approach | |
| JP2024503000A5 (enExample) | ||
| Adesokan et al. | SARS-CoV-2: vaccinology and emerging therapeutics; challenges and future developments | |
| Abdessalem et al. | Research advancements in nanoparticles and cell-based drug delivery systems for the targeted killing of cancer cells | |
| Habibizadeh et al. | Nanoparticle-mediated gene delivery of TRAIL to resistant cancer cells: a review | |
| Xing et al. | Research progress of nanoparticles in diagnosis and treatment of hepatocellular carcinoma | |
| Abdel-Rashid et al. | Fabrication of gold nanoparticles in absence of surfactant as in vitro carrier of plasmid DNA | |
| Ermi et al. | Gene Therapy Strategies for Hepatocellular Carcinoma (HCC): Current Landscape and Future Directions |